These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
532 related items for PubMed ID: 17150102
1. Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation. Noro R, Gemma A, Kosaihira S, Kokubo Y, Chen M, Seike M, Kataoka K, Matsuda K, Okano T, Minegishi Y, Yoshimura A, Kudoh S. BMC Cancer; 2006 Dec 06; 6():277. PubMed ID: 17150102 [Abstract] [Full Text] [Related]
2. Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation. Han SW, Kim TY, Jeon YK, Hwang PG, Im SA, Lee KH, Kim JH, Kim DW, Heo DS, Kim NK, Chung DH, Bang YJ. Clin Cancer Res; 2006 Apr 15; 12(8):2538-44. PubMed ID: 16638863 [Abstract] [Full Text] [Related]
3. Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines. Li H, Schmid-Bindert G, Wang D, Zhao Y, Yang X, Su B, Zhou C. Adv Med Sci; 2011 Apr 15; 56(2):275-84. PubMed ID: 22037177 [Abstract] [Full Text] [Related]
4. Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA). Kokubo Y, Gemma A, Noro R, Seike M, Kataoka K, Matsuda K, Okano T, Minegishi Y, Yoshimura A, Shibuya M, Kudoh S. Br J Cancer; 2005 May 09; 92(9):1711-9. PubMed ID: 15870831 [Abstract] [Full Text] [Related]
5. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels. Helfrich BA, Raben D, Varella-Garcia M, Gustafson D, Chan DC, Bemis L, Coldren C, Barón A, Zeng C, Franklin WA, Hirsch FR, Gazdar A, Minna J, Bunn PA. Clin Cancer Res; 2006 Dec 01; 12(23):7117-25. PubMed ID: 17145836 [Abstract] [Full Text] [Related]
6. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. Ono M, Hirata A, Kometani T, Miyagawa M, Ueda S, Kinoshita H, Fujii T, Kuwano M. Mol Cancer Ther; 2004 Apr 01; 3(4):465-72. PubMed ID: 15078990 [Abstract] [Full Text] [Related]
12. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines. Festuccia C, Muzi P, Millimaggi D, Biordi L, Gravina GL, Speca S, Angelucci A, Dolo V, Vicentini C, Bologna M. Endocr Relat Cancer; 2005 Dec 08; 12(4):983-98. PubMed ID: 16322337 [Abstract] [Full Text] [Related]
13. Buccal mucosa cells as in vivo model to evaluate gefitinib activity in patients with advanced non small cell lung cancer. Loprevite M, Tiseo M, Chiaramondia M, Capelletti M, Bozzetti C, Bortesi B, Naldi N, Nizzoli R, Dadati P, Kunkl A, Zennaro D, Lagrasta C, Campanini N, Spiritelli E, Camisa R, Grossi F, Rindi G, Franciosi V, Ardizzoni A. Clin Cancer Res; 2007 Nov 01; 13(21):6518-26. PubMed ID: 17975165 [Abstract] [Full Text] [Related]
14. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells. Erjala K, Sundvall M, Junttila TT, Zhang N, Savisalo M, Mali P, Kulmala J, Pulkkinen J, Grenman R, Elenius K. Clin Cancer Res; 2006 Jul 01; 12(13):4103-11. PubMed ID: 16818711 [Abstract] [Full Text] [Related]
15. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells. Hirata A, Hosoi F, Miyagawa M, Ueda S, Naito S, Fujii T, Kuwano M, Ono M. Cancer Res; 2005 May 15; 65(10):4253-60. PubMed ID: 15899817 [Abstract] [Full Text] [Related]
16. Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations. Yamamoto C, Basaki Y, Kawahara A, Nakashima K, Kage M, Izumi H, Kohno K, Uramoto H, Yasumoto K, Kuwano M, Ono M. Cancer Res; 2010 Nov 01; 70(21):8715-25. PubMed ID: 20959484 [Abstract] [Full Text] [Related]
17. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. Engelman JA, Mukohara T, Zejnullahu K, Lifshits E, Borrás AM, Gale CM, Naumov GN, Yeap BY, Jarrell E, Sun J, Tracy S, Zhao X, Heymach JV, Johnson BE, Cantley LC, Jänne PA. J Clin Invest; 2006 Oct 01; 116(10):2695-706. PubMed ID: 16906227 [Abstract] [Full Text] [Related]
18. An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review). Ferrer-Soler L, Vazquez-Martin A, Brunet J, Menendez JA, De Llorens R, Colomer R. Int J Mol Med; 2007 Jul 01; 20(1):3-10. PubMed ID: 17549382 [Abstract] [Full Text] [Related]
19. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. Hirsch FR, Varella-Garcia M, Bunn PA, Franklin WA, Dziadziuszko R, Thatcher N, Chang A, Parikh P, Pereira JR, Ciuleanu T, von Pawel J, Watkins C, Flannery A, Ellison G, Donald E, Knight L, Parums D, Botwood N, Holloway B. J Clin Oncol; 2006 Nov 01; 24(31):5034-42. PubMed ID: 17075123 [Abstract] [Full Text] [Related]
20. CpG hypermethylation contributes to decreased expression of PTEN during acquired resistance to gefitinib in human lung cancer cell lines. Maeda M, Murakami Y, Watari K, Kuwano M, Izumi H, Ono M. Lung Cancer; 2015 Mar 01; 87(3):265-71. PubMed ID: 25638724 [Abstract] [Full Text] [Related] Page: [Next] [New Search]